Chronic Fatigue Drug Moving Slowly: Ampligen Gets "Complete Response"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's "complete response" letter for Hemispherx Biopharma's Ampligen cites the full gamut of problems that could have come up for the NDA